Core Insights - Diamond Hill Capital's "Mid Strategy" reported a strong performance in Q4 2025, with a return of 3.65% compared to the Russell Midcap Index's 0.16% [1] - The strategy's year-to-date return was 13.47%, outperforming the Russell Midcap Index's 10.60% [1] - AI-related spending was a significant driver in equity markets, although investor caution emerged in December 2025 [1] Company Overview: Zoetis Inc. (NYSE:ZTS) - Zoetis Inc. is a leader in the animal health market, focusing on medications, vaccines, and diagnostic products for both companion animals and livestock [3] - As of March 17, 2026, Zoetis Inc. shares closed at $121.68, with a market capitalization of approximately $53.624 billion [2] - The stock experienced a -5.77% return in the past month and a -25.69% decline over the past twelve months [2] Investment Positioning - Concerns regarding an arthritis drug for dogs have negatively impacted Zoetis Inc.'s share price, creating an opportunity for investment below intrinsic value estimates [3] - Despite its potential, Zoetis Inc. is not among the 40 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, down from 72 in the previous quarter [4] - The company is viewed as having less upside potential compared to certain AI stocks, which are considered to carry less downside risk [4]

Core Insights - Jensen Investment Management's fourth-quarter investor letter for the "Jensen Quality Growth Equity Strategy" indicates that the strategy underperformed the S&P 500 Index in Q4 2025, returning -0.55% compared to the Index's 2.66% [1] - The underperformance was primarily attributed to the Industrials sector and the outperformance of low-quality stocks, highlighting a current market trend characterized by concentration in mega-cap technology [1] - The portfolio is strategically positioned to benefit from growth in AI and digital transformation while focusing on quality, cash generation, and durability for long-term shareholder returns [1] Company-Specific Insights - Zoetis Inc. (NYSE:ZTS), an animal health company, was highlighted in the investor letter, with its stock closing at $122.23 on March 05, 2026 [2] - Over the past month, Zoetis Inc. experienced a -4.07% return and a significant -28.26% decline over the past twelve months, with a market capitalization of approximately $53.866 billion [2] - The Quality Growth Investment Team liquidated positions in Zoetis Inc. along with Accenture (ACN) and Amphenol (APH) during the quarter [3]

Fundsmith Equity Fund Performance - Fundsmith Equity Fund's T Class Accumulation shares returned 0.8% in 2025, underperforming the MSCI World Index which returned 12.8% [1] - Since inception, the fund has outperformed the index by 1.7% per annum [1] - Underperformance in 2025 attributed to index concentration, growth of assets in Index Funds, and dollar weakness [1] Investment Focus and Strategy - Fundsmith Equity Fund highlighted Zoetis Inc. (NYSE:ZTS) as a key investment in its fourth-quarter 2025 letter [2][3] - The fund sold stakes in Brown-Forman and PepsiCo, and began purchasing Zoetis, EssilorLuxottica, Intuit, and Wolters Kluwer [3] - Zoetis is recognized as a leading veterinary pharmaceutical company, benefiting from long-term growth in pet healthcare spending [3] Zoetis Inc. Overview - Zoetis Inc. reported a market capitalization of $56.36 billion [2] - The company generated revenue of $2.4 billion in Q3 2025, reflecting a 1% increase on a reported basis and 4% on an organic operational basis [4] - Zoetis's share price faced challenges due to concerns over side effects from its drug Librela, although it remains prescribed by veterinarians [3] Hedge Fund Interest - Zoetis Inc. was held by 72 hedge fund portfolios at the end of Q3 2025, a slight decrease from 75 in the previous quarter [4] - Despite its potential, the company is not among the 30 most popular stocks among hedge funds [4]